Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus target price of $4.50 for the company, according to Zacks. Zacks has also given ContraVir Pharmaceuticals an industry rank of 158 out of 265 based on the ratings given to related companies.

Separately, Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 19th.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after acquiring an additional 366,192 shares during the quarter. Vanguard Group Inc. owned 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent filing with the Securities and Exchange Commission. 6.65% of the stock is currently owned by institutional investors.

Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at $0.33 on Friday. The company has a market capitalization of $25.84, a price-to-earnings ratio of -1.38 and a beta of 1.43. ContraVir Pharmaceuticals has a 1 year low of $0.32 and a 1 year high of $1.96.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at

About ContraVir Pharmaceuticals

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.